GalNAc Pathway-based Cell Surface Metabolic Glycoengineering Service

GalNAc Pathway-Based Cell Surface Metabolic Glycoengineering (MGE) in Anti-tumor Vaccines

GalNAc pathway-based cell surface MGE utilizes intracellular metabolic pathways to introduce the GalNAc (N-acetylcysteine) pathway into cell surface glycan modification, which enables GalNAc modification on the cell surface to show controllable and modulatability. Moreover, it is of great importance in protein stability, degradation, and regulation of intercellular interactions, and has important application prospects in anti-tumor vaccines. This technology allows customized design of vaccines based on specific tumor types and individual characteristics. The antigenic specificity, immunogenicity, and stability of vaccines are optimized by precise control of cell surface glycan modifications. Tumors are often accompanied by immune tolerance and immune escape. This technology is used to modulate cell-surface glycan modification, thereby reducing the immunosuppressive signals of tumor cells and improving the tumor-suppressive immune environment to achieve enhanced anti-tumor immune response.

Fig.1 Potential ex-vivo-based clinical applications of MGE. (Agatemor, et al., 2019) Fig.1 Potential ex-vivo-based clinical applications of MGE. (Agatemor, et al., 2019)

GalNAc Pathway-based Cell Surface MGE Service at CD BioGlyco

CD BioGlyco provides clients with advanced GalNAc pathway-based cell surface MGE services using our integrated Glycoengineering Platform, which enables precise control of cell surface glycan modification and offers broad applications in biopharmaceuticals and research. The details of services are as follows:

  • Vector construction
    We first select a suitable expression host and introduce the target protein genes to be modified into the host cells.
  • Processes of modification
    We provide substrate supply by adding exogenous GalNAc, e.g., UDP-GalNAc, GalNAc-α-azide, etc., or by modulating the expression of the relevant intracellular enzymes. Then we utilize genetic engineering techniques to introduce genes for specific enzymes for intracellular expression, such as GalNAc transferase, synthetase, and modification enzymes. We control the rate and selectivity of the enzyme-catalyzed reaction by regulating the expression level of the introduced enzyme, enzyme activity, or intracellular environmental conditions. In the presence of enzymes introduced into the cell, substrates are converted to specific glycan structures and attached to proteins or lipids on the cell surface.
  • Purification and characterization
    We purify the modified proteins and perform quality analysis to ensure that the quality and quantity of modifications are as expected.

Fig.2 The process of our service. (CD BioGlyco)Fig.2 The process of our service. (CD BioGlyco)

Applications

  • In biopharmaceuticals, the stability and activity of recombinant proteins will be improved by modifying glycan modifications on the cell surface to enhance pharmaceutical efficiency.
  • During protein purification, precise control of glycan modifications modulates the adhesion and affinity of proteins, thereby improving the purification efficiency and yield of proteins.
  • This technology can be applied in disease biomarker research to discover new biomarkers by quantitatively and qualitatively analyzing cell surface glycan modifications

Advantages of Us

  • Through in-depth consultations and a comprehensive understanding of the desired outcomes, we ensure that the experimental plan aligns perfectly with the research needs.
  • With a strong emphasis on technical proficiency, our team members possess a deep understanding of industry best practices, cutting-edge technologies, and innovative solutions.
  • By providing a reliable and stable manufacturing process, we aim to instill confidence in our customers, knowing that our products are consistently produced to meet the highest standards and specifications.

CD BioGlyco provides reliable GalNAc pathway-based cell surface MGE service. Our team of experts achieves custom modification and regulation of cell surface glycan modification by manipulating the GalNAc pathway, providing you with differentiated solutions in different fields of research and applications. If you need the related services, please contact us for more information.

Reference

  1. Agatemor, C.; et al. Exploiting metabolic glycoengineering to advance healthcare. Nature Reviews Chemistry. 2019, 3(10): 605-620.
This service is for Research Use Only, not intended for any clinical use.

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0